HC Wainwright & Co. Maintains Buy on Compass Pathways, Lowers Price Target to $65
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Compass Pathways (NASDAQ:CMPS) with a Buy and lowers the price target from $70 to $65.
Stocks · News reference
Why Is Neuronetics Stock Soaring Monday?
BTIG initiates coverage on Neuronetics (STIM) with a Buy rating and $5 target as shares surge 28%. Read the details here.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Morgan Stanley Maintains Overweight on Compass Pathways, Raises Price Target to $18
Morgan Stanley analyst Judah Frommer maintains Compass Pathways (NASDAQ:CMPS) with a Overweight and raises the price target from $17 to $18.
RBC Capital Maintains Outperform on Compass Pathways, Lowers Price Target to $21
RBC Capital analyst Leonid Timashev maintains Compass Pathways (NASDAQ:CMPS) with a Outperform and lowers the price target from $22 to $21.
B. Riley Securities Maintains Buy on Compass Pathways, Raises Price Target to $22
B. Riley Securities analyst Madison El-Saadi maintains Compass Pathways (NASDAQ:CMPS) with a Buy and raises the price target from $17 to $22.
8-K filing — Neuronetics, Inc. (STIM)
Filed: 2026-08-17 AccNo: 0001193125-26-354051 Size: 137 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
BTIG Maintains Buy on Neuronetics, Raises Price Target to $6
BTIG analyst Sam Eiber maintains Neuronetics (NASDAQ:STIM) with a Buy and raises the price target from $5 to $6.